Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 9:13:1443-1456.
doi: 10.2147/IJN.S147759. eCollection 2018.

Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

Xingmei Duan #  1   2 , Minjie Mu #  3 , Junfeng Yan  1 , Lan Bai  1 , Lei Zhong  1 , Yuxuan Zhu  1 , Haixia Pan  1 , Mei Zhang  3 , Jianyou Shi  1   3
Affiliations

Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

Xingmei Duan et al. Int J Nanomedicine. .

Abstract

Background: The newly synthesized Aurora-A kinase inhibitor XY-4 is a potential anti-cancer agent, but its hydrophobicity and limited efficiency restrict further application. Nanotechnology based combined therapy provides an optimized strategy for solving these issues.

Methods: In this study, the newly synthesized Aurora-A kinase inhibitor XY-4 and Bcl-xl _targeted siRNA were co-delivered by cationic liposomes, creating an injectable co-delivery formulation. The anti-cancer ability and mechanisms of XY-4/Bcl-xl siRNA co-loaded cationic liposomes were studied both in vitro and in vivo.

Results: The prepared liposomes had a mean particle size of 91.3±4.5 nm with a zeta potential of 38.5±0.5 mV and were monodispersed (Polydispersity index =0.183) in water solution, with high drug loading capacity and stability. Intriguingly, the positive charges of co-delivery liposomes not only facilitated gene delivery, but also obviously enhanced drug uptake. The XY-4/Bcl-xl siRNA co-loaded cationic liposomes demonstrated enhanced anti-cancer effects on B16 melanoma cells in vitro by activation mitochondrial apoptosis pathway. Moreover, intratumoral injection of this co-delivery formulation efficiently inhibited the growth of a B16 melanoma xenograft model in vivo.

Conclusion: By co-delivering Aurora-A kinase inhibitor XY-4 and Bcl-xl _targeting siRNA in a nanoformulation, our study supplied a potential combination strategy for melanoma therapy.

Keywords: Aurora-A kinase inhibitor; RNA interference; apoptosis; co-delivery; liposome; melanoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Molecular structures of Aurora-A kinase inhibitor XY-4.
Figure 2
Figure 2
Scheme of XY-4/Bcl-xl siRNA co-loaded cationic liposome.
Figure 3
Figure 3
Characterization of XY-4/Bcl-xl siRNA co-loaded cationic liposomes. (A) Size distribution; (B) zeta potential; (C) siRNA retarding assay.
Figure 4
Figure 4
In vitro drug release behaviors of XY-4/Bcl-xl siRNA co-loaded cationic liposomes (siBcl-xl-CLP).
Figure 5
Figure 5
Transfection efficiency of prepared cationic liposomes. (A) Transfection efficiency of cationic liposomes (CLP) and PEI25K (PEI), counted by flow cytometry; (B) picture of transfected B16 cells in normal light under microscope; (C) picture of transfected B16 cells in fluorescent light under microscope 100×, scale bar represents 100 µm (the same field of vision as B).
Figure 6
Figure 6
Enhanced cell uptake by B16 melanoma cells; hydrophobic coumarin-6 was used as the fluorescence (fluor) probe. The fluorescence was observed under microscope (100×).
Figure 7
Figure 7
Inhibition of cell cycle progression by XY-4 on B16 cells. (A) cell cycle distribution of XY-4 treated cells and control group by flow cytometry; (B) statistical analysis of cycle distribution in G1, S and G2/M phase based on flow cytometry results. Cell cycle of XY-4 treated cell was obviously distributed from G1 and S phase into G2/M phase, (**p<0.05).
Figure 8
Figure 8
(A) Anti-cancer abilities of free XY-4 on B16 cells; (B) mRNA level of Bcl-xl was obviously reduced by both two concentration of cationic liposome delivered Bcl-xl siRNA (**p<0.05).
Figure 9
Figure 9
Anti-cancer effect of free Bcl-xl siRNA (siBcl-xl-CLP) and XY-4 combination. The results of the 400:1 and 800:1 combination groups (mol/mol) demonstrated obvious anti-cancer effects.
Figure 10
Figure 10
Anti-cancer abilities of different formulations containing XY-4 or/and Bcl-xl siRNA against B16 cells after treatment for 72 h (CLP= cationic liposome).
Figure 11
Figure 11
XY-4/Bcl-xl siRNA co-loaded cationic liposomes (XY-4/siBcl-xl-CLP) induced apoptosis in B16 melanoma cells. (A) Cell apoptosis detected by flow cytometry; (B) cell apoptosis rates of cells from each group. XY-4/siBcl-xl-CLP group demonstrated strong apoptosis compare into Control group (**p<0.05).
Figure 12
Figure 12
XY-4/Bcl-xl siRNA co-loaded cationic liposomes (XY-4/siBcl-xl-CLP) demonstrated stronger effect on activating the mitochondrial based apoptosis signaling pathway than the single drug formulation.
Figure 13
Figure 13
Anticancer effects and safety of XY-4/Bcl-xl siRNA co-loaded cationic liposomes on B16 mouse melanoma xenograft model. (A) Tumor development curve, calculated by tumor volume (CLP= cation liposome); (B) average weight of tumors in each group. Compared with other treatment groups, the co-delivery formulation group achieved a statistically significant reduction in tumor weight (***P<0.001); (C) Bcl-xl mRNA levels in tumors from each group. The co-delivery formulation group achieved a statistically significant reduction in mRNA levels (*P<0.1); (D) histological analysis of mouse tissues; (E) TdT-mediated dUTP nick-end labeling (TUNEL) staining of B16 mouse melanoma xenograft.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new _targeted therapy. Nature. 2007;445(7130):851–857. - PubMed
    1. Lapenna S, Giordano A. Cell cycle kinases as therapeutic _targets for cancer. Nature Rev Drug Discov. 2009;8(7):547–566. - PubMed
    1. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic _targets in cancer. Cell Prolif. 2003;36(3):131–149. - PMC - PubMed

MeSH terms

  NODES
admin 1
Note 1
twitter 2